Global PD-1 and PD-L1 Monoclonal Antibodies Supply, Demand and Key Producers, 2023-2029

Page: 122

Published Date: 03 Dec 2023

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

The global PD-1 and PD-L1 Monoclonal Antibodies market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

According to the different tumor immune mechanisms, the most studied immunotherapy currently mainly includes cellular immunotherapy and immune checkpoint inhibitor therapy. Among them, the immune checkpoint inhibitor that can be used clinically has cytotoxic T lymphocyte-associated antigen 4 (cytotoxic T lymphocyte-associated antigen 4). ' lymphocyte associated antigen-4, CTLA-4) and programmed cell death protein-1 (programmed cell death protein-1, PD-1)/programmed cell death-ligand 1 (programmed cell death-ligand 1, PD- L1). This report studies PD-1 and PD-L1 monoclonal antibodies.

This report studies the global PD-1 and PD-L1 Monoclonal Antibodies demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for PD-1 and PD-L1 Monoclonal Antibodies, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of PD-1 and PD-L1 Monoclonal Antibodies that contribute to its increasing demand across many markets.

Highlights and key features of the study
Global PD-1 and PD-L1 Monoclonal Antibodies total market, 2018-2029, (USD Million)
Global PD-1 and PD-L1 Monoclonal Antibodies total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: PD-1 and PD-L1 Monoclonal Antibodies total market, key domestic companies and share, (USD Million)
Global PD-1 and PD-L1 Monoclonal Antibodies revenue by player and market share 2018-2023, (USD Million)
Global PD-1 and PD-L1 Monoclonal Antibodies total market by Type, CAGR, 2018-2029, (USD Million)
Global PD-1 and PD-L1 Monoclonal Antibodies total market by Application, CAGR, 2018-2029, (USD Million).

This reports profiles major players in the global PD-1 and PD-L1 Monoclonal Antibodies market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Merck, Bristol-Myers Squibb, Roche, Pfizer, Astrazeneca, Novartis, Biocad, Sanofi/Regeneron Pharmaceuticals and Beigene, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World PD-1 and PD-L1 Monoclonal Antibodies market.

Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global PD-1 and PD-L1 Monoclonal Antibodies Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global PD-1 and PD-L1 Monoclonal Antibodies Market, Segmentation by Type
PD-1 Monoclonal Antibody
PD-L1 Monoclonal Antibody

Global PD-1 and PD-L1 Monoclonal Antibodies Market, Segmentation by Application
Lung Cancer Treatment
Melanoma Treatment
Bowel Cancer Treatment
Other

Companies Profiled:
Merck
Bristol-Myers Squibb
Roche
Pfizer
Astrazeneca
Novartis
Biocad
Sanofi/Regeneron Pharmaceuticals
Beigene
Jiangsu Hengrui Pharmaceuticals
Innovent Biologics, Inc.

Key Questions Answered
1. How big is the global PD-1 and PD-L1 Monoclonal Antibodies market?
2. What is the demand of the global PD-1 and PD-L1 Monoclonal Antibodies market?
3. What is the year over year growth of the global PD-1 and PD-L1 Monoclonal Antibodies market?
4. What is the total value of the global PD-1 and PD-L1 Monoclonal Antibodies market?
5. Who are the major players in the global PD-1 and PD-L1 Monoclonal Antibodies market?

Table of Contents

1 Supply Summary
    1.1 PD-1 and PD-L1 Monoclonal Antibodies Introduction
    1.2 World PD-1 and PD-L1 Monoclonal Antibodies Market Size & Forecast (2018 & 2022 & 2029)
    1.3 World PD-1 and PD-L1 Monoclonal Antibodies Total Market by Region (by Headquarter Location)
        1.3.1 World PD-1 and PD-L1 Monoclonal Antibodies Market Size by Region (2018-2029), (by Headquarter Location)
        1.3.2 United States PD-1 and PD-L1 Monoclonal Antibodies Market Size (2018-2029)
        1.3.3 China PD-1 and PD-L1 Monoclonal Antibodies Market Size (2018-2029)
        1.3.4 Europe PD-1 and PD-L1 Monoclonal Antibodies Market Size (2018-2029)
        1.3.5 Japan PD-1 and PD-L1 Monoclonal Antibodies Market Size (2018-2029)
        1.3.6 South Korea PD-1 and PD-L1 Monoclonal Antibodies Market Size (2018-2029)
        1.3.7 ASEAN PD-1 and PD-L1 Monoclonal Antibodies Market Size (2018-2029)
        1.3.8 India PD-1 and PD-L1 Monoclonal Antibodies Market Size (2018-2029)
    1.4 Market Drivers, Restraints and Trends
        1.4.1 PD-1 and PD-L1 Monoclonal Antibodies Market Drivers
        1.4.2 Factors Affecting Demand
        1.4.3 PD-1 and PD-L1 Monoclonal Antibodies Major Market Trends

2 Demand Summary
    2.1 World PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2018-2029)
    2.2 World PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Region
        2.2.1 World PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Region (2018-2023)
        2.2.2 World PD-1 and PD-L1 Monoclonal Antibodies Consumption Value Forecast by Region (2024-2029)
    2.3 United States PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2018-2029)
    2.4 China PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2018-2029)
    2.5 Europe PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2018-2029)
    2.6 Japan PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2018-2029)
    2.7 South Korea PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2018-2029)
    2.8 ASEAN PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2018-2029)
    2.9 India PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2018-2029)

3 World PD-1 and PD-L1 Monoclonal Antibodies Companies Competitive Analysis
    3.1 World PD-1 and PD-L1 Monoclonal Antibodies Revenue by Player (2018-2023)
    3.2 Industry Rank and Concentration Rate (CR)
        3.2.1 Global PD-1 and PD-L1 Monoclonal Antibodies Industry Rank of Major Players
        3.2.2 Global Concentration Ratios (CR4) for PD-1 and PD-L1 Monoclonal Antibodies in 2022
        3.2.3 Global Concentration Ratios (CR8) for PD-1 and PD-L1 Monoclonal Antibodies in 2022
    3.3 PD-1 and PD-L1 Monoclonal Antibodies Company Evaluation Quadrant
    3.4 PD-1 and PD-L1 Monoclonal Antibodies Market: Overall Company Footprint Analysis
        3.4.1 PD-1 and PD-L1 Monoclonal Antibodies Market: Region Footprint
        3.4.2 PD-1 and PD-L1 Monoclonal Antibodies Market: Company Product Type Footprint
        3.4.3 PD-1 and PD-L1 Monoclonal Antibodies Market: Company Product Application Footprint
    3.5 Competitive Environment
        3.5.1 Historical Structure of the Industry
        3.5.2 Barriers of Market Entry
        3.5.3 Factors of Competition
    3.6 Mergers, Acquisitions Activity

4 United States VS China VS Rest of the World (by Headquarter Location)
    4.1 United States VS China: PD-1 and PD-L1 Monoclonal Antibodies Revenue Comparison (by Headquarter Location)
        4.1.1 United States VS China: PD-1 and PD-L1 Monoclonal Antibodies Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
        4.1.2 United States VS China: PD-1 and PD-L1 Monoclonal Antibodies Revenue Market Share Comparison (2018 & 2022 & 2029)
    4.2 United States Based Companies VS China Based Companies: PD-1 and PD-L1 Monoclonal Antibodies Consumption Value Comparison
        4.2.1 United States VS China: PD-1 and PD-L1 Monoclonal Antibodies Consumption Value Comparison (2018 & 2022 & 2029)
        4.2.2 United States VS China: PD-1 and PD-L1 Monoclonal Antibodies Consumption Value Market Share Comparison (2018 & 2022 & 2029)
    4.3 United States Based PD-1 and PD-L1 Monoclonal Antibodies Companies and Market Share, 2018-2023
        4.3.1 United States Based PD-1 and PD-L1 Monoclonal Antibodies Companies, Headquarters (States, Country)
        4.3.2 United States Based Companies PD-1 and PD-L1 Monoclonal Antibodies Revenue, (2018-2023)
    4.4 China Based Companies PD-1 and PD-L1 Monoclonal Antibodies Revenue and Market Share, 2018-2023
        4.4.1 China Based PD-1 and PD-L1 Monoclonal Antibodies Companies, Company Headquarters (Province, Country)
        4.4.2 China Based Companies PD-1 and PD-L1 Monoclonal Antibodies Revenue, (2018-2023)
    4.5 Rest of World Based PD-1 and PD-L1 Monoclonal Antibodies Companies and Market Share, 2018-2023
        4.5.1 Rest of World Based PD-1 and PD-L1 Monoclonal Antibodies Companies, Headquarters (States, Country)
        4.5.2 Rest of World Based Companies PD-1 and PD-L1 Monoclonal Antibodies Revenue, (2018-2023)

5 Market Analysis by Type
    5.1 World PD-1 and PD-L1 Monoclonal Antibodies Market Size Overview by Type: 2018 VS 2022 VS 2029
    5.2 Segment Introduction by Type
        5.2.1 PD-1 Monoclonal Antibody
        5.2.2 PD-L1 Monoclonal Antibody
    5.3 Market Segment by Type
        5.3.1 World PD-1 and PD-L1 Monoclonal Antibodies Market Size by Type (2018-2023)
        5.3.2 World PD-1 and PD-L1 Monoclonal Antibodies Market Size by Type (2024-2029)
        5.3.3 World PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Type (2018-2029)

6 Market Analysis by Application
    6.1 World PD-1 and PD-L1 Monoclonal Antibodies Market Size Overview by Application: 2018 VS 2022 VS 2029
    6.2 Segment Introduction by Application
        6.2.1 Lung Cancer Treatment
        6.2.2 Melanoma Treatment
        6.2.3 Bowel Cancer Treatment
        6.2.4 Other
        6.2.5 Other
    6.3 Market Segment by Application
        6.3.1 World PD-1 and PD-L1 Monoclonal Antibodies Market Size by Application (2018-2023)
        6.3.2 World PD-1 and PD-L1 Monoclonal Antibodies Market Size by Application (2024-2029)
        6.3.3 World PD-1 and PD-L1 Monoclonal Antibodies Market Size by Application (2018-2029)

7 Company Profiles
    7.1 Merck
        7.1.1 Merck Details
        7.1.2 Merck Major Business
        7.1.3 Merck PD-1 and PD-L1 Monoclonal Antibodies Product and Services
        7.1.4 Merck PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
        7.1.5 Merck Recent Developments/Updates
        7.1.6 Merck Competitive Strengths & Weaknesses
    7.2 Bristol-Myers Squibb
        7.2.1 Bristol-Myers Squibb Details
        7.2.2 Bristol-Myers Squibb Major Business
        7.2.3 Bristol-Myers Squibb PD-1 and PD-L1 Monoclonal Antibodies Product and Services
        7.2.4 Bristol-Myers Squibb PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
        7.2.5 Bristol-Myers Squibb Recent Developments/Updates
        7.2.6 Bristol-Myers Squibb Competitive Strengths & Weaknesses
    7.3 Roche
        7.3.1 Roche Details
        7.3.2 Roche Major Business
        7.3.3 Roche PD-1 and PD-L1 Monoclonal Antibodies Product and Services
        7.3.4 Roche PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
        7.3.5 Roche Recent Developments/Updates
        7.3.6 Roche Competitive Strengths & Weaknesses
    7.4 Pfizer
        7.4.1 Pfizer Details
        7.4.2 Pfizer Major Business
        7.4.3 Pfizer PD-1 and PD-L1 Monoclonal Antibodies Product and Services
        7.4.4 Pfizer PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
        7.4.5 Pfizer Recent Developments/Updates
        7.4.6 Pfizer Competitive Strengths & Weaknesses
    7.5 Astrazeneca
        7.5.1 Astrazeneca Details
        7.5.2 Astrazeneca Major Business
        7.5.3 Astrazeneca PD-1 and PD-L1 Monoclonal Antibodies Product and Services
        7.5.4 Astrazeneca PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
        7.5.5 Astrazeneca Recent Developments/Updates
        7.5.6 Astrazeneca Competitive Strengths & Weaknesses
    7.6 Novartis
        7.6.1 Novartis Details
        7.6.2 Novartis Major Business
        7.6.3 Novartis PD-1 and PD-L1 Monoclonal Antibodies Product and Services
        7.6.4 Novartis PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
        7.6.5 Novartis Recent Developments/Updates
        7.6.6 Novartis Competitive Strengths & Weaknesses
    7.7 Biocad
        7.7.1 Biocad Details
        7.7.2 Biocad Major Business
        7.7.3 Biocad PD-1 and PD-L1 Monoclonal Antibodies Product and Services
        7.7.4 Biocad PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
        7.7.5 Biocad Recent Developments/Updates
        7.7.6 Biocad Competitive Strengths & Weaknesses
    7.8 Sanofi/Regeneron Pharmaceuticals
        7.8.1 Sanofi/Regeneron Pharmaceuticals Details
        7.8.2 Sanofi/Regeneron Pharmaceuticals Major Business
        7.8.3 Sanofi/Regeneron Pharmaceuticals PD-1 and PD-L1 Monoclonal Antibodies Product and Services
        7.8.4 Sanofi/Regeneron Pharmaceuticals PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
        7.8.5 Sanofi/Regeneron Pharmaceuticals Recent Developments/Updates
        7.8.6 Sanofi/Regeneron Pharmaceuticals Competitive Strengths & Weaknesses
    7.9 Beigene
        7.9.1 Beigene Details
        7.9.2 Beigene Major Business
        7.9.3 Beigene PD-1 and PD-L1 Monoclonal Antibodies Product and Services
        7.9.4 Beigene PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
        7.9.5 Beigene Recent Developments/Updates
        7.9.6 Beigene Competitive Strengths & Weaknesses
    7.10 Jiangsu Hengrui Pharmaceuticals
        7.10.1 Jiangsu Hengrui Pharmaceuticals Details
        7.10.2 Jiangsu Hengrui Pharmaceuticals Major Business
        7.10.3 Jiangsu Hengrui Pharmaceuticals PD-1 and PD-L1 Monoclonal Antibodies Product and Services
        7.10.4 Jiangsu Hengrui Pharmaceuticals PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
        7.10.5 Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
        7.10.6 Jiangsu Hengrui Pharmaceuticals Competitive Strengths & Weaknesses
    7.11 Innovent Biologics, Inc.
        7.11.1 Innovent Biologics, Inc. Details
        7.11.2 Innovent Biologics, Inc. Major Business
        7.11.3 Innovent Biologics, Inc. PD-1 and PD-L1 Monoclonal Antibodies Product and Services
        7.11.4 Innovent Biologics, Inc. PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
        7.11.5 Innovent Biologics, Inc. Recent Developments/Updates
        7.11.6 Innovent Biologics, Inc. Competitive Strengths & Weaknesses

8 Industry Chain Analysis
    8.1 PD-1 and PD-L1 Monoclonal Antibodies Industry Chain
    8.2 PD-1 and PD-L1 Monoclonal Antibodies Upstream Analysis
    8.3 PD-1 and PD-L1 Monoclonal Antibodies Midstream Analysis
    8.4 PD-1 and PD-L1 Monoclonal Antibodies Downstream Analysis

9 Research Findings and Conclusion

10 Appendix
    10.1 Methodology
    10.2 Research Process and Data Source
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. World PD-1 and PD-L1 Monoclonal Antibodies Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
    Table 2. World PD-1 and PD-L1 Monoclonal Antibodies Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
    Table 3. World PD-1 and PD-L1 Monoclonal Antibodies Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
    Table 4. World PD-1 and PD-L1 Monoclonal Antibodies Revenue Market Share by Region (2018-2023), (by Headquarter Location)
    Table 5. World PD-1 and PD-L1 Monoclonal Antibodies Revenue Market Share by Region (2024-2029), (by Headquarter Location)
    Table 6. Major Market Trends
    Table 7. World PD-1 and PD-L1 Monoclonal Antibodies Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
    Table 8. World PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Region (2018-2023) & (USD Million)
    Table 9. World PD-1 and PD-L1 Monoclonal Antibodies Consumption Value Forecast by Region (2024-2029) & (USD Million)
    Table 10. World PD-1 and PD-L1 Monoclonal Antibodies Revenue by Player (2018-2023) & (USD Million)
    Table 11. Revenue Market Share of Key PD-1 and PD-L1 Monoclonal Antibodies Players in 2022
    Table 12. World PD-1 and PD-L1 Monoclonal Antibodies Industry Rank of Major Player, Based on Revenue in 2022
    Table 13. Global PD-1 and PD-L1 Monoclonal Antibodies Company Evaluation Quadrant
    Table 14. Head Office of Key PD-1 and PD-L1 Monoclonal Antibodies Player
    Table 15. PD-1 and PD-L1 Monoclonal Antibodies Market: Company Product Type Footprint
    Table 16. PD-1 and PD-L1 Monoclonal Antibodies Market: Company Product Application Footprint
    Table 17. PD-1 and PD-L1 Monoclonal Antibodies Mergers & Acquisitions Activity
    Table 18. United States VS China PD-1 and PD-L1 Monoclonal Antibodies Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
    Table 19. United States VS China PD-1 and PD-L1 Monoclonal Antibodies Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
    Table 20. United States Based PD-1 and PD-L1 Monoclonal Antibodies Companies, Headquarters (States, Country)
    Table 21. United States Based Companies PD-1 and PD-L1 Monoclonal Antibodies Revenue, (2018-2023) & (USD Million)
    Table 22. United States Based Companies PD-1 and PD-L1 Monoclonal Antibodies Revenue Market Share (2018-2023)
    Table 23. China Based PD-1 and PD-L1 Monoclonal Antibodies Companies, Headquarters (Province, Country)
    Table 24. China Based Companies PD-1 and PD-L1 Monoclonal Antibodies Revenue, (2018-2023) & (USD Million)
    Table 25. China Based Companies PD-1 and PD-L1 Monoclonal Antibodies Revenue Market Share (2018-2023)
    Table 26. Rest of World Based PD-1 and PD-L1 Monoclonal Antibodies Companies, Headquarters (States, Country)
    Table 27. Rest of World Based Companies PD-1 and PD-L1 Monoclonal Antibodies Revenue, (2018-2023) & (USD Million)
    Table 28. Rest of World Based Companies PD-1 and PD-L1 Monoclonal Antibodies Revenue Market Share (2018-2023)
    Table 29. World PD-1 and PD-L1 Monoclonal Antibodies Market Size by Type, (USD Million), 2018 & 2022 & 2029
    Table 30. World PD-1 and PD-L1 Monoclonal Antibodies Market Size by Type (2018-2023) & (USD Million)
    Table 31. World PD-1 and PD-L1 Monoclonal Antibodies Market Size by Type (2024-2029) & (USD Million)
    Table 32. World PD-1 and PD-L1 Monoclonal Antibodies Market Size by Application, (USD Million), 2018 & 2022 & 2029
    Table 33. World PD-1 and PD-L1 Monoclonal Antibodies Market Size by Application (2018-2023) & (USD Million)
    Table 34. World PD-1 and PD-L1 Monoclonal Antibodies Market Size by Application (2024-2029) & (USD Million)
    Table 35. Merck Basic Information, Area Served and Competitors
    Table 36. Merck Major Business
    Table 37. Merck PD-1 and PD-L1 Monoclonal Antibodies Product and Services
    Table 38. Merck PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 39. Merck Recent Developments/Updates
    Table 40. Merck Competitive Strengths & Weaknesses
    Table 41. Bristol-Myers Squibb Basic Information, Area Served and Competitors
    Table 42. Bristol-Myers Squibb Major Business
    Table 43. Bristol-Myers Squibb PD-1 and PD-L1 Monoclonal Antibodies Product and Services
    Table 44. Bristol-Myers Squibb PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 45. Bristol-Myers Squibb Recent Developments/Updates
    Table 46. Bristol-Myers Squibb Competitive Strengths & Weaknesses
    Table 47. Roche Basic Information, Area Served and Competitors
    Table 48. Roche Major Business
    Table 49. Roche PD-1 and PD-L1 Monoclonal Antibodies Product and Services
    Table 50. Roche PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 51. Roche Recent Developments/Updates
    Table 52. Roche Competitive Strengths & Weaknesses
    Table 53. Pfizer Basic Information, Area Served and Competitors
    Table 54. Pfizer Major Business
    Table 55. Pfizer PD-1 and PD-L1 Monoclonal Antibodies Product and Services
    Table 56. Pfizer PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 57. Pfizer Recent Developments/Updates
    Table 58. Pfizer Competitive Strengths & Weaknesses
    Table 59. Astrazeneca Basic Information, Area Served and Competitors
    Table 60. Astrazeneca Major Business
    Table 61. Astrazeneca PD-1 and PD-L1 Monoclonal Antibodies Product and Services
    Table 62. Astrazeneca PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 63. Astrazeneca Recent Developments/Updates
    Table 64. Astrazeneca Competitive Strengths & Weaknesses
    Table 65. Novartis Basic Information, Area Served and Competitors
    Table 66. Novartis Major Business
    Table 67. Novartis PD-1 and PD-L1 Monoclonal Antibodies Product and Services
    Table 68. Novartis PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 69. Novartis Recent Developments/Updates
    Table 70. Novartis Competitive Strengths & Weaknesses
    Table 71. Biocad Basic Information, Area Served and Competitors
    Table 72. Biocad Major Business
    Table 73. Biocad PD-1 and PD-L1 Monoclonal Antibodies Product and Services
    Table 74. Biocad PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 75. Biocad Recent Developments/Updates
    Table 76. Biocad Competitive Strengths & Weaknesses
    Table 77. Sanofi/Regeneron Pharmaceuticals Basic Information, Area Served and Competitors
    Table 78. Sanofi/Regeneron Pharmaceuticals Major Business
    Table 79. Sanofi/Regeneron Pharmaceuticals PD-1 and PD-L1 Monoclonal Antibodies Product and Services
    Table 80. Sanofi/Regeneron Pharmaceuticals PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 81. Sanofi/Regeneron Pharmaceuticals Recent Developments/Updates
    Table 82. Sanofi/Regeneron Pharmaceuticals Competitive Strengths & Weaknesses
    Table 83. Beigene Basic Information, Area Served and Competitors
    Table 84. Beigene Major Business
    Table 85. Beigene PD-1 and PD-L1 Monoclonal Antibodies Product and Services
    Table 86. Beigene PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 87. Beigene Recent Developments/Updates
    Table 88. Beigene Competitive Strengths & Weaknesses
    Table 89. Jiangsu Hengrui Pharmaceuticals Basic Information, Area Served and Competitors
    Table 90. Jiangsu Hengrui Pharmaceuticals Major Business
    Table 91. Jiangsu Hengrui Pharmaceuticals PD-1 and PD-L1 Monoclonal Antibodies Product and Services
    Table 92. Jiangsu Hengrui Pharmaceuticals PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 93. Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
    Table 94. Innovent Biologics, Inc. Basic Information, Area Served and Competitors
    Table 95. Innovent Biologics, Inc. Major Business
    Table 96. Innovent Biologics, Inc. PD-1 and PD-L1 Monoclonal Antibodies Product and Services
    Table 97. Innovent Biologics, Inc. PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 98. Global Key Players of PD-1 and PD-L1 Monoclonal Antibodies Upstream (Raw Materials)
    Table 99. PD-1 and PD-L1 Monoclonal Antibodies Typical Customers
List of Figure
    Figure 1. PD-1 and PD-L1 Monoclonal Antibodies Picture
    Figure 2. World PD-1 and PD-L1 Monoclonal Antibodies Total Market Size: 2018 & 2022 & 2029, (USD Million)
    Figure 3. World PD-1 and PD-L1 Monoclonal Antibodies Total Market Size (2018-2029) & (USD Million)
    Figure 4. World PD-1 and PD-L1 Monoclonal Antibodies Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
    Figure 5. World PD-1 and PD-L1 Monoclonal Antibodies Revenue Market Share by Region (2018-2029), (by Headquarter Location)
    Figure 6. United States Based Company PD-1 and PD-L1 Monoclonal Antibodies Revenue (2018-2029) & (USD Million)
    Figure 7. China Based Company PD-1 and PD-L1 Monoclonal Antibodies Revenue (2018-2029) & (USD Million)
    Figure 8. Europe Based Company PD-1 and PD-L1 Monoclonal Antibodies Revenue (2018-2029) & (USD Million)
    Figure 9. Japan Based Company PD-1 and PD-L1 Monoclonal Antibodies Revenue (2018-2029) & (USD Million)
    Figure 10. South Korea Based Company PD-1 and PD-L1 Monoclonal Antibodies Revenue (2018-2029) & (USD Million)
    Figure 11. ASEAN Based Company PD-1 and PD-L1 Monoclonal Antibodies Revenue (2018-2029) & (USD Million)
    Figure 12. India Based Company PD-1 and PD-L1 Monoclonal Antibodies Revenue (2018-2029) & (USD Million)
    Figure 13. PD-1 and PD-L1 Monoclonal Antibodies Market Drivers
    Figure 14. Factors Affecting Demand
    Figure 15. World PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2018-2029) & (USD Million)
    Figure 16. World PD-1 and PD-L1 Monoclonal Antibodies Consumption Value Market Share by Region (2018-2029)
    Figure 17. United States PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2018-2029) & (USD Million)
    Figure 18. China PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2018-2029) & (USD Million)
    Figure 19. Europe PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2018-2029) & (USD Million)
    Figure 20. Japan PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2018-2029) & (USD Million)
    Figure 21. South Korea PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2018-2029) & (USD Million)
    Figure 22. ASEAN PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2018-2029) & (USD Million)
    Figure 23. India PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2018-2029) & (USD Million)
    Figure 24. Producer Shipments of PD-1 and PD-L1 Monoclonal Antibodies by Player Revenue ($MM) and Market Share (%): 2022
    Figure 25. Global Four-firm Concentration Ratios (CR4) for PD-1 and PD-L1 Monoclonal Antibodies Markets in 2022
    Figure 26. Global Four-firm Concentration Ratios (CR8) for PD-1 and PD-L1 Monoclonal Antibodies Markets in 2022
    Figure 27. United States VS China: PD-1 and PD-L1 Monoclonal Antibodies Revenue Market Share Comparison (2018 & 2022 & 2029)
    Figure 28. United States VS China: PD-1 and PD-L1 Monoclonal Antibodies Consumption Value Market Share Comparison (2018 & 2022 & 2029)
    Figure 29. World PD-1 and PD-L1 Monoclonal Antibodies Market Size by Type, (USD Million), 2018 & 2022 & 2029
    Figure 30. World PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Type in 2022
    Figure 31. PD-1 Monoclonal Antibody
    Figure 32. PD-L1 Monoclonal Antibody
    Figure 33. World PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Type (2018-2029)
    Figure 34. World PD-1 and PD-L1 Monoclonal Antibodies Market Size by Application, (USD Million), 2018 & 2022 & 2029
    Figure 35. World PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Application in 2022
    Figure 36. Lung Cancer Treatment
    Figure 37. Melanoma Treatment
    Figure 38. Bowel Cancer Treatment
    Figure 39. Other
    Figure 40. PD-1 and PD-L1 Monoclonal Antibodies Industrial Chain
    Figure 41. Methodology
    Figure 42. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Merck
Bristol-Myers Squibb
Roche
Pfizer
Astrazeneca
Novartis
Biocad
Sanofi/Regeneron Pharmaceuticals
Beigene
Jiangsu Hengrui Pharmaceuticals
Innovent Biologics, Inc.

Related Reports

Global PD-1 and PD-L1 Monoclonal Antibodies Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Global PD-1 and PD-L1 Monoclonal Antibodies Market 2023 by Company, Regions, Type and Application, Forecast to 2029

date 03 Dec 2023

date Pharma & Healthcare

According to our (Global Info Research) latest study, the global PD-1 and PD-L1 Monoclonal Antibodies market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period.

Global PD-1 and PD-L1 Monoclonal Antibodies Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Global PD-1 and PD-L1 Monoclonal Antibodies Market 2024 by Company, Regions, Type and Application, Forecast to 2030

date 25 Jan 2024

date Pharma & Healthcare

According to our (Global Info Research) latest study, the global PD-1 and PD-L1 Monoclonal Antibodies market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.

Product Tags

PD-1 and PD-L1 Monoclonal Antibodies

GABA Supplements

L-carnitine Capsule

Opical Thrombin

Purchase Options

Single User License

USD4480.00

Multi User License

USD6720.00

Corporate Users License

USD8960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>